These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 7541325)

  • 21. Recombinant human granulocyte colony-stimulating factor in preterm neonates with sepsis and relative neutropenia: a randomized, single-blind, non-placebo-controlled trial.
    Gathwala G; Walia M; Bala H; Singh S
    J Trop Pediatr; 2012 Feb; 58(1):12-8. PubMed ID: 21296862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.
    Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y; Ohe Y
    Eur J Cancer; 1994; 30A(2):188-94. PubMed ID: 7512356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
    Mehdi SA; Perry MC; Herndon JE; Crawford J; Young R; Graziano SL
    J Interferon Cytokine Res; 1998 Aug; 18(8):623-7. PubMed ID: 9726444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study.
    Liu C; Hao Y; Wang L; Meng F; Wen F; Zhong D
    Thorac Cancer; 2021 Apr; 12(8):1154-1161. PubMed ID: 33590721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer--multi-center randomized crossover study].
    Katakami N; Hasegawa T; Umeda B; Adachi S; Ishii N; Takada Y; Tsubota N; Nakano K; Tamura R; Nakai H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 May; 34(5):520-8. PubMed ID: 8753109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X; Xu L; Pan P; Xu Z; Wang A; Li Y
    Thorac Cancer; 2022 Jan; 13(1):117-125. PubMed ID: 34791805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-intensive chemotherapy in extensive-stage small-cell lung cancer.
    Negoro S; Masuda N; Furuse K; Saijo N; Fukuoka M
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S70-3. PubMed ID: 9272138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant granulocyte colony-stimulating factor induces production of human neutrophil peptides in lung cancer patients with neutropenia.
    Ashitani J; Nakazato M; Mukae H; Taniguchi H; Date Y; Matsukura S
    Regul Pept; 2000 Nov; 95(1-3):87-92. PubMed ID: 11062337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RhG-CSF improves radiation-induced myelosuppression and survival in the canine exposed to fission neutron irradiation.
    Yu ZY; Li M; Han AR; Xing S; Ou HL; Xiong GL; Xie L; Zhao YF; Xiao H; Shan YJ; Zhao ZH; Liu XL; Cong YW; Luo QL
    J Radiat Res; 2011; 52(4):472-80. PubMed ID: 21785235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    Jiang Y; Zhang J; Zhong J; Liao H; Zhang J; Liu Y; Liang Y; Li H
    BMC Cancer; 2023 Jul; 23(1):702. PubMed ID: 37495949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
    Tjan-Heijnen VC; Biesma B; Festen J; Splinter TA; Cox A; Wagener DJ; Postmus PE
    J Clin Oncol; 1998 Aug; 16(8):2708-14. PubMed ID: 9704721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
    Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
    Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients.
    Fukuda M; Oka M; Ishida Y; Kinoshita H; Terashi K; Fukuda M; Kawabata S; Kinoshita A; Soda H; Kohno S
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1947-51. PubMed ID: 11408206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
    Oyama A; Ota K; Asano S; Takaku F; Miyazaki T; Uzuka Y; Omine M; Furusawa S; Hirashima K; Sanpi K
    Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1619-34. PubMed ID: 1700040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
    Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
    Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
    Oyama A; Ota K; Asano S; Takaku F; Yoshida Y; Uzuka Y; Omine M; Furusawa S; Takatani O; Sawada U
    Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2533-48. PubMed ID: 1702132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.